Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
ALL
MCID: LKM062
MIFTS: 69

Leukemia, Acute Lymphoblastic (ALL)

Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Leukemia, Acute Lymphoblastic

About this section

MalaCards integrated aliases for Leukemia, Acute Lymphoblastic:

Name: Leukemia, Acute Lymphoblastic 56 73 37
Acute Lymphoblastic Leukemia 12 74 52 58 29 6 15 17
Acute Lymphocytic Leukemia 74 52 58 42 71
All 56 12 52 58 73
Leukemia, Acute Lymphocytic, Susceptibility to, 1 56 13
Leukemia, Acute Lymphoblastic, Susceptibility to 29 6
Precursor Lymphoblastic Lymphoma/leukemia 12 17
B-Cell Acute Lymphoblastic Leukemia 36 17
Acute Lymphoblastic Leukaemia 12 15
Leukemia, Acute Lymphoblastic, Susceptibility to, 3 71
Precursor Cell Lymphoblastic Leukemia-Lymphoma 43
Precursor Cell Lymphoblastic Leukemia Lymphoma 71
Leukemia Acute Lymphoblastic B-Hyperdiploid 73
Childhood Acute Lymphoblastic Leukemia 73
Lymphoblastic Leukemia Acute Childhood 54
Acute Lymphoblastic Leukemia/lymphoma 58
Leukemia B-Cell Acute Lymphoblastic 73
Leukemia T-Cell Acute Lymphoblastic 73
Leukemia, Acute Lymphoblastic, 3 73
Leukemia, Lymphocytic, Acute, L1 71
Leukemia Acute Lymphoblastic 1 73
Leukemia, Acute, Lymphoblastic 39
Leukemia, Acute Lymphocytic 1 56
Leukemia Acute Lymphocytic 1 73
Lymphoblastic Leukemia Acute 54
Acute Lymphocytic Leukaemia 12
Leukemia Acute Lymphocytic 73
All3 73
All1 73

Characteristics:

Orphanet epidemiological data:

58
acute lymphoblastic leukemia
Prevalence: 1-9/100000 (France),1-9/100000 (United States),1-5/10000 (United States),1-5/10000 (Europe); Age of onset: All ages; Age of death: any age;

HPO:

31
leukemia, acute lymphoblastic:
Inheritance polygenic inheritance


Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases Genetic diseases
Anatomical: Blood diseases Immune diseases
See all MalaCards categories (disease lists)
ICD10: 32 33
Orphanet: 58  
Rare haematological diseases


External Ids:

Disease Ontology 12 DOID:9952
OMIM 56 613065
KEGG 36 H00001
ICD9CM 34 204.0
MeSH 43 D054198
NCIt 49 C3167 C7055
SNOMED-CT 67 91857003
ICD10 32 C91.0 C91.00
ICD10 via Orphanet 33 C91.0
UMLS via Orphanet 72 C0023449
Orphanet 58 ORPHA513
SNOMED-CT via HPO 68 128822004
UMLS 71 C0023449 C0023452 C1335469 more
Sources

Summaries for Leukemia, Acute Lymphoblastic

About this section
NIH Rare Diseases : 52 Acute lymphoblastic leukemia (ALL) is a type of cancer in which the bone marrow makes too many lymphocytes (a type of white blood cell ). It may develop in children or adults. ALL spreads to the blood fairly quickly, and then may spread to other areas of the body such as the lymph nodes , liver, spleen, central nervous system , and testicles (in males). Signs and symptoms of ALL may include fever, easy bruising or bleeding, feeling tired, loss of appetite, pain in the bones or abdomen, and painless lumps in the neck, underarm, stomach, or groin. ALL is typically caused by random, non-inherited changes in the DNA of immature lymphocytes called lymphoblasts. However, some people may inherit a genetic susceptibility to developing ALL. The risk to develop ALL may also be increased by past treatment for cancer, and by having certain genetic conditions or syndromes . Having one or more risk factors does not mean that a person definitely will develop ALL. Treatment of ALL depends on the person's age, how advanced the cancer is, and whether certain genetic changes are found in cancer cells . Treatment options may involve systemic and/or intrathecal chemotherapy , radiation therapy , targeted therapy , and/or a stem cell transplant . Biologic therapy and chimeric antigen receptor (CAR) T-cell therapy are currently being studied as treatment options and may be used when other therapies are not working. The chance of recovery also depends on many factors. With treatment, about 98% of children with ALL go into remission , and 85% of those with first-time ALL are expected have no long-term complications. The chance of recovery for adults is not as high, as 20-40% of adults are cured with current treatments.

MalaCards based summary : Leukemia, Acute Lymphoblastic, also known as acute lymphoblastic leukemia, is related to leukemia, acute lymphoblastic 3 and t-cell acute lymphoblastic leukemia, and has symptoms including edema, chest pain and angina pectoris. An important gene associated with Leukemia, Acute Lymphoblastic is PAX5 (Paired Box 5), and among its related pathways/superpathways are Transcriptional misregulation in cancer and MicroRNAs in cancer. The drugs Teniposide and Micafungin have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are acute lymphoblastic leukemia and neoplasm

Disease Ontology : 12 A acute leukemia that is characterized by over production of lymphoblasts.

OMIM : 56 Acute lymphoblastic leukemia (ALL), also known as acute lymphocytic leukemia, is a subtype of acute leukemia, a cancer of the white blood cells. Somatically acquired mutations in several genes have been identified in ALL lymphoblasts, cells in the early stages of differentiation. Germline variation in certain genes may also predispose to susceptibility to ALL (Trevino et al., 2009). (613065)

MedlinePlus : 42 Leukemia is cancer of the white blood cells. White blood cells help your body fight infection. Your blood cells form in your bone marrow. In leukemia, however, the bone marrow produces abnormal white blood cells. These cells crowd out the healthy blood cells, making it hard for blood to do its work. In acute lymphocytic leukemia (ALL), also called acute lymphoblastic leukemia, there are too many of specific types of white blood cells called lymphocytes or lymphoblasts. ALL is the most common type of cancer in children. Possible risk factors for ALL include being male, being white, previous chemotherapy treatment, exposure to radiation, and for adults, being older than 70. Symptoms of ALL include: Weakness or feeling tired Fever Easy bruising or bleeding Bleeding under the skin Shortness of breath Weight loss or loss of appetite Pain in the bones or stomach Pain or a feeling of fullness below the ribs Painless lumps in the neck, underarm, stomach, or groin Tests that examine the blood and bone marrow diagnose ALL. Treatments include chemotherapy, radiation therapy, stem cell transplants, and targeted therapy. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. Once the leukemia is in remission, you need additional treatment to make sure that it does not come back. NIH: National Cancer Institute

KEGG : 36 Acute lymphocytic leukemia (ALL) is a clonal stem cell malignancy of excessive lymphoblast proliferation. It is now understood that ALL and lymphoblastic lymphoma are the same disease entities at the morphologic and immunophenotypic levels and classified as either B- and T-cell lymphoblastic leukemia/lymphoma (B-ALL and T-ALL). In the case of B-ALL, numerous reports have demonstrated that recurring genetic abnormalities are associated with sufficiently unique clinical, immunophenotypic, and/or prognostic features so that they can be considered as distinct entities. The most common rearrangements observed in B-ALL are the t(12;21) (p13;q22) rearrangement resulting in expression of the ETV6-RUNX1 fusion (TEL-AML1); the t(1;19) (q23;p13) translocation that results in expression of the TCF3 (E2A) fusion partner, (also known as TCF3) TFPT-PBX1 fusion (E2A-PBX); the t(9;22) (q34;q11.2) "Philadelphia" chromosome resulting in expression of the BCR-ABL1 fusion; and rearrangements of MLL (also known as KMT2A) at 11q23 to a diverse array of fusion partners. If none of these specific genetic abnormalities are found, the designation of "B lymphoblastic leukemia/lymphoma, not otherwise specified," is appropriate.

UniProtKB/Swiss-Prot : 73 Leukemia, acute lymphoblastic: A subtype of acute leukemia, a cancer of the white blood cells. ALL is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.
Leukemia, acute lymphoblastic, 3: A subtype of acute leukemia, a cancer of the white blood cells. Acute lymphoblastic anemia is a malignant disease of bone marrow and the most common malignancy diagnosed in children. The malignant cells are lymphoid precursor cells (lymphoblasts) that are arrested in an early stage of development. The lymphoblasts replace the normal marrow elements, resulting in a marked decrease in the production of normal blood cells. Consequently, anemia, thrombocytopenia, and neutropenia occur to varying degrees. The lymphoblasts also proliferate in organs other than the marrow, particularly the liver, spleen, and lymphnodes.

Wikipedia : 74 Acute lymphoblastic leukemia (ALL) is a cancer of the lymphoid line of blood cells characterized by the... more...

Sources

Related Diseases for Leukemia, Acute Lymphoblastic

About this section

Diseases in the Leukemia, Acute Lymphoblastic family:

Leukemia, Acute Lymphoblastic 2 Leukemia, Acute Lymphoblastic 3

Diseases related to Leukemia, Acute Lymphoblastic via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1298)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute lymphoblastic 3 35.4 PAX5 FLT3 ETV6
2 t-cell acute lymphoblastic leukemia 34.0 NALT1 MIR223 FLT3 ETV6
3 myelofibrosis 32.0 MIR223 FLT3 ETV6 CDKN2B-AS1
4 lymphoma, non-hodgkin, familial 31.9 PAX5 NBN MIR155 FLT3 ETV6 ACTB
5 leukemia, acute myeloid 31.9 PAX5 MIR335 MIR223 MIR155 FLT3 ETV6
6 leukemia, chronic lymphocytic 31.7 PAX5 MIR223 MIR155 GNB1 FLT3 ACTB
7 hematologic cancer 31.7 XIST PAX5 MIR335 MIR223 MIR196B MIR155
8 leukemia, acute monocytic 31.6 MIR155 FLT3 ACTB
9 retinitis pigmentosa 11 31.3 XIST MIR335 ACTB
10 b-lymphoblastic leukemia/lymphoma with iamp21 31.2 PAX5 ETV6
11 dermatomyositis 31.0 MIR335 MIR223 MIR155
12 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 31.0 FLT3 ETV6
13 leukemia, acute lymphoblastic 2 12.6
14 acute lymphoblastic leukemia congenital sporadic aniridia 12.4
15 childhood b-cell acute lymphoblastic leukemia 12.3
16 childhood t-cell acute lymphoblastic leukemia 12.3
17 b-cell adult acute lymphocytic leukemia 12.1
18 null-cell leukemia 11.9
19 mixed phenotype acute leukemia 11.8
20 medulloblastoma 11.8
21 lymphoblastic leukemia, acute, with lymphomatous features 11.5
22 b-lymphoblastic leukemia/lymphoma with tcf3-pbx1 11.5
23 t-cell adult acute lymphocytic leukemia 11.5
24 pdgfra-associated chronic eosinophilic leukemia 11.4
25 leukemia 11.0
26 pancreatic ductal adenocarcinoma 10.9 MIR223 MIR203A MIR196B MIR155
27 miyoshi muscular dystrophy 1 10.9 MIR335 MIR223 MIR155
28 female reproductive system disease 10.9 MIR335 MIR223 MIR196B MIR155
29 reproductive system disease 10.9 MIR335 MIR223 MIR196B MIR155
30 nemaline myopathy 10.8 MIR335 MIR223 MIR155
31 leiomyoma, uterine 10.7 MIR335 MIR203A MIR196B
32 aspergillosis 10.7
33 hepatic veno-occlusive disease 10.6
34 cebpa-associated familial acute myeloid leukemia 10.6 FLT3 ETV6
35 chromosomal triplication 10.6
36 osteonecrosis 10.6
37 myeloma, multiple 10.5
38 mental retardation, autosomal dominant 33 10.5 PAX5 ETV6
39 central nervous system leukemia 10.5
40 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 10.5
41 spindle cell sarcoma 10.5
42 myeloproliferative neoplasm 10.5
43 down syndrome 10.5
44 lipid metabolism disorder 10.5
45 severe combined immunodeficiency 10.5
46 acute leukemia 10.5
47 mucositis 10.4
48 48,xyyy 10.4
49 central nervous system disease 10.4
50 nervous system disease 10.4

Graphical network of the top 20 diseases related to Leukemia, Acute Lymphoblastic:



Diseases related to Leukemia, Acute Lymphoblastic
Sources

Symptoms & Phenotypes for Leukemia, Acute Lymphoblastic

About this section

Human phenotypes related to Leukemia, Acute Lymphoblastic:

31
# Description HPO Frequency HPO Source Accession
1 acute lymphoblastic leukemia 31 HP:0006721

Clinical features from OMIM:

613065

UMLS symptoms related to Leukemia, Acute Lymphoblastic:


edema, chest pain, angina pectoris

MGI Mouse Phenotypes related to Leukemia, Acute Lymphoblastic:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 neoplasm MP:0002006 9.1 ACTB ETV6 FLT3 NBN PAX5 PMS2
Sources

Drugs & Therapeutics for Leukemia, Acute Lymphoblastic

About this section

Drugs for Leukemia, Acute Lymphoblastic (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 550)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Micafungin Approved, Investigational Phase 4 235114-32-6 477468 3081921
3
Posaconazole Approved, Investigational, Vet_approved Phase 4 171228-49-2 147912
4
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
5
Hydroxocobalamin Approved Phase 4 13422-51-0 15589840 11953898
6
Oprelvekin Approved, Investigational Phase 4 145941-26-0
7
Epirubicin Approved Phase 4 56420-45-2 41867
8
Decitabine Approved, Investigational Phase 4 2353-33-5 451668
9
Iron Approved, Experimental Phase 4 15438-31-0, 7439-89-6 27284 23925
10
Metformin Approved Phase 4 657-24-9 14219 4091
11
Nicotine Approved Phase 4 54-11-5 942 89594
12
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
13
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
14
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
15
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
16
Vitamin D3 Approved, Nutraceutical Phase 4 67-97-0 5280795 6221
17
Calcifediol Approved, Nutraceutical Phase 4 19356-17-3 5283731 6433735
18
Cobalamin Experimental Phase 4 13408-78-1 6857388
19 Imatinib Mesylate Phase 4 220127-57-1 123596
20 Hormone Antagonists Phase 4
21
Ethylene Phase 4 74-85-1 6325
22 Vitamin B 6 Phase 4
23 Vitamin B 12 Phase 4
24 Vitamin B12 Phase 4
25 Liver Extracts Phase 4
26 Hypoglycemic Agents Phase 4
27 HH-GV-678 Phase 4
28 Iron Chelating Agents Phase 4
29 Heptavalent Pneumococcal Conjugate Vaccine Phase 4
30 Calciferol Phase 4
31 Ergocalciferols Phase 4
32 Hydroxycholecalciferols Phase 4
33 Vitamin D2 Phase 4
34 Adrenergic Agents Phase 4
35 Atomoxetine Hydrochloride Phase 4
36
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
37
Mercaptopurine Approved Phase 3 50-44-2 667490
38
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
39
Methylprednisolone hemisuccinate Approved Phase 3 2921-57-5
40
Prednisolone phosphate Approved, Vet_approved Phase 3 302-25-0
41 Prednisolone acetate Approved, Vet_approved Phase 3 52-21-1
42
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
43
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
44
Lorazepam Approved Phase 3 846-49-1 3958
45
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
46
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
47
Zoledronic Acid Approved Phase 3 118072-93-8 68740
48
Rasburicase Approved, Investigational Phase 3 134774-45-1
49
Iodine Approved, Investigational Phase 3 7553-56-2 807
50
Cobalt Approved, Experimental Phase 3 7440-48-4 104729

Interventional clinical trials:

(show top 50) (show all 2031)
# Name Status NCT ID Phase Drugs
1 Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) Unknown status NCT00198978 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Cytarabine;Idarubicin;Granulocyte-Colony-Stimulating Factor;Mercaptopurine;Methotrexate;Rituximab;HDARAC;Vincristine;Depocyte;Asparaginase
2 Philadelphia -Negative High-risk Children Acute Lymphoblastic Leukemia(ALL) Treatment:Induction Therapy:Vincristine(V),Idarubicin(I),L-asparaginase(L),Dexamethasone(D);Consolidation:V+Daunorubicin(D)+L+D, Methotrexate,Cytarabine Unknown status NCT01990807 Phase 4 Idarubicin(IDA)
3 German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) Unknown status NCT00198991 Phase 4 Cyclophosphamide;Dexamethasone;Vincristine;daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Prednisolone;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Cladribine
4 Ma-Spore ALL 2010 Study Unknown status NCT02894645 Phase 4 Prednisolone;Dexamethasone;L-Asparaginase;Vincristine;Methotrexate;Daunorubicin;Doxorubicin;Cyclophosphamide;Cytarabine;6-Mercaptopurine;Thioguanine;Fludarabine;Imatinib
5 PEG-asparaginase During Two Treatment Courses in the Treatment of Childhood Acute Lymphoblastic Leukemia Unknown status NCT00192673 Phase 4 PEG-asparaginase
6 Medical Research Council Working Party on Leukaemia in Children UK National Acute Lymphoblastic Leukaemia (ALL) Trial: UKALL 2003 Unknown status NCT00222612 Phase 4 Standard childhood UK ALL protocol;Intensified treatment including Capizzi maintenance
7 Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province Unknown status NCT00846703 Phase 4 6-mercaptopurine, Methotrexate;6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone
8 Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. Unknown status NCT01906671 Phase 4 Xaluprine;Puri-Nethol
9 The Combination of Lower Dosage of Chemotherapy With Tyrosine Kinase Inhibitor to Treat Newly Diagnosed ph+ Acute Lymphoblastic Leukemia Patients Unknown status NCT02690922 Phase 4 Dasatinib;prednisone;dexamethasone;methotrexate
10 Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults Unknown status NCT00797810 Phase 4 Rituximab
11 An Open-label,Multi-center,Prospective Study of Idarubicin and Etoposide Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation for Adult Acute Lymphoblastic Leukemia Unknown status NCT01873807 Phase 4 IDA;CTX;VP-16
12 ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY Unknown status NCT01901666 Phase 4 Growth Hormone
13 Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia Completed NCT00199095 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone;Idarubicin;Ifosfamide;Methotrexate;Mercaptopurine;VM26;Vincristine
14 Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia Completed NCT01358253 Phase 4 Cyclophosphamide;Doxorubicin;Vincristine;Dexamethasone;Cytarabine;Methotrexate;Rituximab;6-Mercaptopurine;Prednisone;L-asparaginase
15 Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) Completed NCT00199069 Phase 4 Asparaginase;Vincristine;Daunorubicin, Adriamycin;Cyclophosphamide;Ifosfamide;Cytarabine;Mitoxantrone;Methotrexate;6-Mercaptopurine;6-Thioguanine;VM26;Dexamethasone / Prednisolone
16 Pulses of Vincristine and Dexamethasone During Maintenance in BFM Protocols for Children With Intermediate-Risk Acute Lymphoblastic Leukemia Completed NCT00411541 Phase 4 vincristine;dexamethasone
17 German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) Completed NCT00199004 Phase 4 Cyclophosphamide;Dexamethasone / Prednisolone;Vincristine;Daunorubicin;Asparaginase;Methotrexate;Cytarabine;Mercaptopurine;G-CSF;Vindesine;VP16;Adriamycin;Thioguanine;VM26;Rituximab
18 A Randomized Open-Label Trial of Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic Syndrome Completed NCT01200355 Phase 4 micafungin;posaconazole
19 Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) Completed NCT00199056 Phase 4 Dexamethasone / Prednisolone;Cyclophosphamide;Methotrexate;Vincristine / Vindesine;Daunorubicin;Asparaginase;G-CSF;Cytarabine;6-Mercaptopurine;VP16;Adriamycin;Thioguanine;VM26;Idarubicin;Fludarabine;Ifosfamide
20 Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) Completed NCT00199017 Phase 4 Dexamethasone/Prednisolone;Cyclophosphamide;Vincristine;Daunorubicin;Asparaginase;G-CSF;Mercaptopurine;Cytarabine;Methotrexate;VP16;Vindesine;Adriamycin;Thioguanine;HDARAC;Cladribine
21 The Study on the Pharmacokinetics of Pegylated Recombinant Human Granulocyte Stimulating Factor（PEG-rhG-CSF） in Children and Adolescents Completed NCT02953730 Phase 4 PEG-rhG-CSF
22 ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia Completed NCT00114348 Phase 4
23 Learning Impairments Among Survivors of Childhood Cancer Completed NCT00576472 Phase 4 Methylphenidate
24 Multicenter Study to Optimise Therapy of B-ALL, Burkitt's NHL and High-Grade Non-Hodgkin's Lymphoma in Adults (Amend 7) Completed NCT00199082 Phase 4 Adriamycin;Cyclophosphamide;Cytarabine;Dexamethasone/Prednisolone;VP16;Ifosfamide;Methotrexate;G-CSF;Rituximab;Vincristine/Vindesine
25 Treatment of High Risk Adult Acute Lymphoblastic Leukemia Completed NCT00853008 Phase 4 Vincristine;Daunorubicin;Prednisone;Mitoxantrone;Cytosine Arabinoside;Dexamethasone;Methotrexate (MTX);Cytarabine;ASP;Mercaptopurine;Teniposide;Hydrocortisone
26 LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive Completed NCT00526305 Phase 4 Vincristine;Daunorubicin;Prednisone;L-Asparaginase;Mitoxantrone;Cytosine Arabinoside;Hydrocortisone;Mercaptopurine;Cyclophosphamide;Dexamethasone
27 Effect of Treatment Using rhIL-11 in Patients With Thrombocytopenia After Chemotherapy for Childhood Acute Lymphoblastic Leukemia Completed NCT02314273 Phase 4 rhIL-11
28 LAL-BR/2001: Study Treatment to Low Risk ALL Completed NCT00526175 Phase 4 Prednisone;Vincristine;Daunorubicin;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside;Mercaptopurine;VP-16
29 PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia Completed NCT00494897 Phase 4 Asparaginase;Cyclophosphamide;Cytarabine;Daunorubicin;Mercaptopurine;Prednisone;Vincristine;Methotrexate
30 LAL-AR-N-2005: Study Treatment for Children High Risk Acute Lymphoblastic Leukemia Completed NCT00526409 Phase 4 Prednisolone;Daunorubicin;Vincristine;L-Asparaginase;Cyclophosphamide;Methotrexate;Cytosine Arabinoside
31 Evaluation of Allogeneic Marrow Transplants Depleted of T-Cells by CD34+ Selection in Patients Undergoing Transplantation With an Unrelated Matched or 1 Antigen Mismatched Donor or a 1 Antigen Mismatched Related Donor Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
32 Neuroprotective Effect of Vitamin B12 and Vitamin B6 Against Vincristine Induced Peripheral Neuropathy: A Randomized, Double Blind, Placebo Controlled, Multi Center Trial Completed NCT02923388 Phase 4 Injection Mecobalamin,;Tablet Pyridoxine hydrochloride;Intravenous normal saline 1 ml;Placebo pill
33 A PHASE 4, OPEN-LABEL, RANDOMIZED STUDY OF TWO INOTUZUMAB OZOGAMICIN DOSE LEVELS IN ADULT PATIENTS WITH RELAPSED OR REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA ELIGIBLE FOR HEMATOPOIETIC STEM CELL TRANSPLANTATION AND WHO HAVE RISK FACTOR(S) FOR VENO-OCCLUSIVE DISEASE Recruiting NCT03677596 Phase 4 inotuzumab ozogamicin-dose level 2;Inotuzumab ozogamicin-dose level 1
34 Identification of New Immune Factors Specific of Relapse in Childhood B Lineage Acute Lymphoblastic Leukemia Recruiting NCT02618109 Phase 4
35 A Study of Efficacy and Safety of Flumatinib Combined With Chemotherapy in the Treatment of Ph Positive Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring Recruiting NCT04375683 Phase 4 Flumatinib
36 Allogeneic Stem Cell Transplant for Children and Adolescents With Acute Lymoblastic Leukemia FORUM - Pharmacogenomic Study (add-on Study) Recruiting NCT02670564 Phase 4
37 PROTOCOL FOR THE TREATMENT Acute Lymphoblastic Leukemia With Ph 'NEGATIVE IN ELDERLY PATIENTS (> 55 Years) Recruiting NCT01366898 Phase 4 Dexamethasona, Idarubicine, ARA-C, Methotrexate
38 A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma Recruiting NCT03558412 Phase 4 Decitabine
39 G-CSF Alone or Combination With GM-CSF on Prevention and Treatment of Infection in Children With Malignant Tumor: a Prospective, Multicentre, Randomised Controlled Trial Recruiting NCT02933333 Phase 4
40 Treatment Protocol For All Fragile Patients Ph' Negative Over 55 Years Recruiting NCT01358201 Phase 4 vINCRISTINE;Dexamethasone;Methotrexate;Cytosine arabinoside
41 Chemotherapy and Imatinib in Young Adults With Acute Lymphoblastic Leukemia Ph (BCR-ABL) POSITIVE Recruiting NCT01491763 Phase 4 Imatinib
42 Hematology , Shanghai Jiaotong University Affiliated Shanghai First People's Hospital, Shanghai, China Recruiting NCT02938741 Phase 4 Anti－human Thymoglobulin;Placebo
43 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Recruiting NCT02984475 Phase 4 Metformin
44 Vaccinating Children After Chemotherapy for Acute Lymphoblastic Leukemia: A Canadian Immunization Research Network Study Active, not recruiting NCT02447718 Phase 4
45 Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic Enrolling by invitation NCT03920813 Phase 4 Mercaptopurine
46 A Randomized Phase IV Control Trial of Single High Dose Oral Vitamin D3 (Stoss Therapy) in Pediatric Patients Undergoing HSCT to Prevent Vitamin D Deficiency and Insufficiency During Transplant Enrolling by invitation NCT03176849 Phase 4
47 ProphyALL - Pilot Study on Safety of Four Weekly Administrations of 7 mg/kg of Liposomal Amphotericin B (AmBisome®) in Antifungal Primary Prophylaxis Treatment of Elderly Patients With Acute Lymphoblastic Leukemia Undergoing Induction Chemotherapy Within the GMALL-Elderly Protocol Terminated NCT00386997 Phase 4 liposomal amphotericin B (AmBisome®)
48 Atomoxetine for Children With Acquired Attentional Disorders Following Completion of Chemotherapy for Acute Lymphocytic Leukemia Terminated NCT00299234 Phase 4 Atomoxetine
49 A Phase-2 Clinical Study to Determine the Efficacy and Safety of Depocyt (Cytarabine Liposome Injection) for the Treatment of CNS Relapse in Adult Patients With Acute Lymphoblastic Leukemia or Very Aggressive Lymphoma Unknown status NCT00199108 Phase 2, Phase 3 Depocyt;Dexamethasone
50 Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia Unknown status NCT01423747 Phase 3 VP16;VP16, ATG;Fludarabine, OKT3, Treosulfan, Thiotepa;VP16, ATG

Search NIH Clinical Center for Leukemia, Acute Lymphoblastic

Inferred drug relations via UMLS 71 / NDF-RT 50 :


ASPARAGINASE
Cyclophosphamide
Idarubicin
Idarubicin Hydrochloride
Ifosfamide
mercaptopurine
pegaspargase
sargramostim

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Leukemia, Acute Lymphoblastic cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Leukemia, Acute Lymphoblastic:
Hemacord, umbilical cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Hematopoietic stem cells for treatment of hematologic malignancies
NiCord, umbilical cord blood-derived stem/progenitor cells for hemotological diseases
Umbilical cord-derived hematopoietic stem cells for treatment of acute lymphoblastic leukemia
Embryonic/Adult Cultured Cells Related to Leukemia, Acute Lymphoblastic:
Umbilical cord blood-derived hematopoietic progenitor cells (HEMACORD) PMIDs: 9828244
Bone marrow-derived hematopoietic stem cells
Umbilical cord blood-derived stem cells (NiCord) PMIDs: 22198152
Umbilical cord blood-derived hematopoietic stem cells (family) PMIDs: 17968329

Cochrane evidence based reviews: precursor cell lymphoblastic leukemia-lymphoma

Sources

Genetic Tests for Leukemia, Acute Lymphoblastic

About this section

Genetic tests related to Leukemia, Acute Lymphoblastic:

# Genetic test Affiliating Genes
1 Acute Lymphoblastic Leukemia 29
2 Leukemia, Acute Lymphoblastic, Susceptibility to 29
Sources

Anatomical Context for Leukemia, Acute Lymphoblastic

About this section

MalaCards organs/tissues related to Leukemia, Acute Lymphoblastic:

40
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Testes, B Lymphoblasts
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Leukemia, Acute Lymphoblastic:
# Tissue Anatomical CompartmentCell Relevance
1 Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells Potential therapeutic candidate
2 Blood Peripheral Blood Mature B-Cells Affected by disease
3 Blood Hematopoietic Bone Marrow Small Pre B-Cells Affected by disease
Sources

Publications for Leukemia, Acute Lymphoblastic

About this section

Articles related to Leukemia, Acute Lymphoblastic:

(show top 50) (show all 25923)
# Title Authors PMID Year
1
FLT3 mutations in childhood acute lymphoblastic leukemia. 61 54 56 6
14670924 2004
2
First case of aplastic anemia in a Japanese child with a homozygous missense mutation in the NBS1 gene (I171V) associated with genomic instability. 54 6 61
15338273 2004
3
Mutations in the Nijmegen Breakage Syndrome gene (NBS1) in childhood acute lymphoblastic leukemia (ALL). 6 54 61
11325820 2001
4
PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia. 61 6
30643249 2019
5
RAG-mediated recombination is the predominant driver of oncogenic rearrangement in ETV6-RUNX1 acute lymphoblastic leukemia. 56 61
24413735 2014
6
Global chromatin profiling reveals NSD2 mutations in pediatric acute lymphoblastic leukemia. 56 61
24076604 2013
7
A recurrent germline PAX5 mutation confers susceptibility to pre-B cell acute lymphoblastic leukemia. 61 6
24013638 2013
8
Exome sequencing identifies mutation in CNOT3 and ribosomal genes RPL5 and RPL10 in T-cell acute lymphoblastic leukemia. 56 61
23263491 2013
9
Genetic inactivation of the polycomb repressive complex 2 in T cell acute lymphoblastic leukemia. 56 61
22237151 2012
10
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. 56 61
21892159 2011
11
PHF6 mutations in T-cell acute lymphoblastic leukemia. 61 56
20228800 2010
12
Verification of the susceptibility loci on 7p12.2, 10q21.2, and 14q11.2 in precursor B-cell acute lymphoblastic leukemia of childhood. 61 56
20042726 2010
13
Rearrangement of CRLF2 in B-progenitor- and Down syndrome-associated acute lymphoblastic leukemia. 56 61
19838194 2009
14
Germline genomic variants associated with childhood acute lymphoblastic leukemia. 61 56
19684603 2009
15
Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia. 61 56
19684604 2009
16
Mutation analysis of the HOX paralogous 4-13 genes in children with acute lymphoid malignancies: identification of a novel germline mutation of HOXD4 leading to a partial loss-of-function. 6 61
15776434 2005
17
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia. 56 61
15361874 2004
18
Hematopoietic malignancies demonstrate loss-of-function mutations of BAX. 56 61
9531611 1998
19
Leukaemia hijacks a neural mechanism to invade the central nervous system. 56
30022166 2018
20
Histidine catabolism is a major determinant of methotrexate sensitivity. 56
29995852 2018
21
Clonal evolution mechanisms in NT5C2 mutant-relapsed acute lymphoblastic leukaemia. 56
29342136 2018
22
Metabolic gatekeeper function of B-lymphoid transcription factors. 56
28192788 2017
23
Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures. 6
27108799 2016
24
Mutations in G protein β subunits promote transformation and kinase inhibitor resistance. 6
25485910 2015
25
Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia. 56
25132549 2014
26
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. 56
25043004 2014
27
The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. 56
22237106 2012
28
BCL6 enables Ph+ acute lymphoblastic leukaemia cells to survive BCR-ABL1 kinase inhibition. 56
21593872 2011
29
CREBBP mutations in relapsed acute lymphoblastic leukaemia. 56
21390130 2011
30
Hypermethylation of specific microRNA genes in MLL-rearranged infant acute lymphoblastic leukemia: major matters at a micro scale. 46 61
21116279 2011
31
Genetic variegation of clonal architecture and propagating cells in leukaemia. 56
21160474 2011
32
Identification of new microRNA genes and aberrant microRNA profiles in childhood acute lymphoblastic leukemia. 61 46
18923441 2009
33
MicroRNA expression signatures accurately discriminate acute lymphoblastic leukemia from acute myeloid leukemia. 61 46
18056805 2007
34
Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. 56
17344859 2007
35
Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. 6
11442493 2001
36
Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. 6
11290608 2001
37
Sequence and analysis of the human ABL gene, the BCR gene, and regions involved in the Philadelphia chromosomal translocation. 56
7665185 1995
38
A new fused transcript in Philadelphia chromosome positive acute lymphocytic leukaemia. 56
2825022 1987
39
A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. 56
3543692 1987
40
Unique forms of the abl tyrosine kinase distinguish Ph1-positive CML from Ph1-positive ALL. 56
3541203 1987
41
Thymoquinone synergizes with arsenic and interferon alpha to target human T-cell leukemia/lymphoma. 42
32272181 2020
42
Comprehensive immunohistochemical analysis of immune checkpoint molecules in adult T cell leukemia/lymphoma. 42
32157421 2020
43
Exosomes mediate intercellular transfer of non-autonomous tolerance to proteasome inhibitors in mixed-lineage leukemia. 42
32058648 2020
44
Polymorphisms of the gamma-glutamyl hydrolase gene and risk of relapse to acute lymphoblastic leukemia in Mexico. 61 54
20197200 2010
45
Association between the methylenetetrahydrofolate reductase polymorphisms and risk of acute lymphoblastic leukemia in Serbian children. 54 61
20445408 2010
46
Glucocorticoid receptor knock down reveals a similar apoptotic threshold but differing gene regulation patterns in T-cell and pre-B-cell acute lymphoblastic leukemia. 61 54
20170710 2010
47
Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia. 61 54
20015871 2010
48
IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. 61 54
20060740 2010
49
Simultaneous detection of MDR1 and WT1 gene expression to predict the prognosis of adult acute lymphoblastic leukemia. 54 61
20423567 2010
50
STAT5 in B cell development and leukemia. 61 54
20227268 2010
Sources

Variations for Leukemia, Acute Lymphoblastic

About this section

ClinVar genetic disease variations for Leukemia, Acute Lymphoblastic:

6 (show all 36) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 PAX5 PAX5, PRO80ARGundetermined variant Pathogenic 624590
2 FLT3 NM_004119.3(FLT3):c.2504A>T (p.Asp835Val)SNV Pathogenic 16272 rs121909646 13:28592641-28592641 13:28018504-28018504
3 FLT3 NM_004119.3(FLT3):c.2503G>T (p.Asp835Tyr)SNV Pathogenic 16276 rs121913488 13:28592642-28592642 13:28018505-28018505
4 FLT3 NM_004119.3(FLT3):c.1777_1779del (p.Asp593del)deletion Pathogenic 16278 rs587776834 13:28608277-28608279 13:28034140-28034142
5 PMS2 NM_000535.7(PMS2):c.1831dup (p.Ile611fs)duplication Pathogenic 91317 rs63750250 7:6026564-6026565 7:5986933-5986934
6 ETV6 NM_001987.4(ETV6):c.1153-5_1153-1delshort repeat Pathogenic 190240 rs786205154 12:12038855-12038859 12:11885921-11885925
7 ETV6 NM_001987.4(ETV6):c.1046T>C (p.Leu349Pro)SNV Pathogenic 190241 rs786205155 12:12037415-12037415 12:11884481-11884481
8 ACTB NP_001092.1(ACTB):p.Val209Leuprotein only Pathogenic 218133
9 NBN NM_002485.4(NBN):c.1903A>T (p.Lys635Ter)SNV Pathogenic/Likely pathogenic 142559 rs587782545 8:90960063-90960063 8:89947835-89947835
10 NBN NM_002485.4(NBN):c.2140C>T (p.Arg714Ter)SNV Pathogenic/Likely pathogenic 182737 rs730881864 8:90955525-90955525 8:89943297-89943297
11 GNB1 NM_002074.5(GNB1):c.239T>A (p.Ile80Asn)SNV Pathogenic/Likely pathogenic 224715 rs752746786 1:1737942-1737942 1:1806503-1806503
12 GNB1 NM_002074.5(GNB1):c.227A>G (p.Asp76Gly)SNV Pathogenic/Likely pathogenic 224711 rs869312821 1:1737954-1737954 1:1806515-1806515
13 NBN NM_002485.4(NBN):c.1030C>T (p.Gln344Ter)SNV Pathogenic/Likely pathogenic 190229 rs767215758 8:90971047-90971047 8:89958819-89958819
14 NBN NM_001024688.2(NBN):c.-141_-140deldeletion Pathogenic/Likely pathogenic 371121 rs767454740 8:90994964-90994965 8:89982736-89982737
15 NBN NM_002485.4(NBN):c.595C>T (p.Pro199Ser)SNV Conflicting interpretations of pathogenicity 127874 rs587780097 8:90983508-90983508 8:89971280-89971280
16 NBN NM_002485.5(NBN):c.1262T>C (p.Leu421Ser)SNV Conflicting interpretations of pathogenicity 127009 rs104895032 8:90967646-90967646 8:89955418-89955418
17 NBN NM_002485.5(NBN):c.628G>T (p.Val210Phe)SNV Conflicting interpretations of pathogenicity 127014 rs61754796 8:90983475-90983475 8:89971247-89971247
18 NBN NM_002485.4(NBN):c.1999T>C (p.Ser667Pro)SNV Conflicting interpretations of pathogenicity 127863 rs587780091 8:90958439-90958439 8:89946211-89946211
19 NBN NM_002485.5(NBN):c.425A>G (p.Asn142Ser)SNV Conflicting interpretations of pathogenicity 127871 rs769414 8:90993017-90993017 8:89980789-89980789
20 NBN NM_002485.4(NBN):c.390A>G (p.Gln130=)SNV Conflicting interpretations of pathogenicity 625984 rs146150499 8:90993052-90993052 8:89980824-89980824
21 NBN NM_002485.5(NBN):c.511A>G (p.Ile171Val)SNV Conflicting interpretations of pathogenicity 6946 rs61754966 8:90990521-90990521 8:89978293-89978293
22 HOXD4 NM_014621.3(HOXD4):c.242A>T (p.Glu81Val)SNV Uncertain significance 14888 rs104893636 2:177016603-177016603 2:176151875-176151875
23 NBN NM_002485.4(NBN):c.503G>A (p.Gly168Glu)SNV Uncertain significance 461570 rs1554566728 8:90990529-90990529 8:89978301-89978301
24 NBN NM_002485.4(NBN):c.11T>G (p.Leu4Arg)SNV Uncertain significance 461493 rs748090667 8:90996779-90996779 8:89984551-89984551
25 NBN NM_002485.4(NBN):c.431C>T (p.Thr144Ile)SNV Uncertain significance 485924 rs1554567906 8:90993011-90993011 8:89980783-89980783
26 PAX5 NM_016734.3(PAX5):c.435G>C (p.Gln145His)SNV Uncertain significance 587563 rs758368747 9:37006510-37006510 9:37006513-37006513
27 NBN NM_002485.4(NBN):c.456G>A (p.Met152Ile)SNV Uncertain significance 127872 rs201816949 8:90992986-90992986 8:89980758-89980758
28 NBN NM_002485.4(NBN):c.505C>T (p.Arg169Cys)SNV Uncertain significance 127873 rs182756889 8:90990527-90990527 8:89978299-89978299
29 NBN NM_002485.4(NBN):c.2149A>T (p.Thr717Ser)SNV Uncertain significance 127865 rs587780093 8:90955516-90955516 8:89943288-89943288
30 NBN NM_002485.4(NBN):c.1034G>T (p.Gly345Val)SNV Uncertain significance 127852 rs587780089 8:90971043-90971043 8:89958815-89958815
31 NBN NM_002485.5(NBN):c.119C>T (p.Ser40Leu)SNV Uncertain significance 141146 rs587781530 8:90995002-90995002 8:89982774-89982774
32 NBN NM_002485.5(NBN):c.2215C>G (p.Leu739Val)SNV Uncertain significance 182730 rs370058152 8:90949273-90949273 8:89937045-89937045
33 NBN NM_002485.4(NBN):c.340G>T (p.Val114Phe)SNV Uncertain significance 219644 rs771034958 8:90993102-90993102 8:89980874-89980874
34 NBN NM_002485.4(NBN):c.361G>C (p.Asp121His)SNV Uncertain significance 231708 rs777916019 8:90993081-90993081 8:89980853-89980853
35 NBN NM_002485.4(NBN):c.775G>A (p.Glu259Lys)SNV Uncertain significance 182716 rs201559159 8:90982713-90982713 8:89970485-89970485
36 NBN NM_002485.4(NBN):c.683T>G (p.Ile228Arg)SNV Uncertain significance 186350 rs777460725 8:90983420-90983420 8:89971192-89971192

UniProtKB/Swiss-Prot genetic disease variations for Leukemia, Acute Lymphoblastic:

73
# Symbol AA change Variation ID SNP ID
1 PAX5 p.Gly183Ser VAR_070682 rs398123063

Copy number variations for Leukemia, Acute Lymphoblastic from CNVD:

7 (show top 50) (show all 2943)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13316 1 1 117600000 Loss Acute lymphoblastic leukemia
2 13371 17 1 22200000 Deletion TP53 Acute lymphoblastic leukemia
3 13410 1 1 2300000 Copy number Acute lymphoblastic leukemia
4 13773 1 1 35400000 Duplication Acute lymphoblastic leukemia
5 13788 1 1 40300000 Duplication Acute lymphoblastic leukemia
6 13790 1 1 46500000 Gain Acute lymphoblastic leukemia
7 13836 12 10000000 12600000 Deletion ETV6 Acute lymphoblastic leukemia
8 13906 1 100818677 103024856 Loss DPH5 Acute lymphoblastic leukemia
9 13907 1 100818677 103024856 Loss EXTL2 Acute lymphoblastic leukemia
10 13908 1 100818677 103024856 Loss OLFM3 Acute lymphoblastic leukemia
11 13909 1 100818677 103024856 Loss S1PR1 Acute lymphoblastic leukemia
12 13910 1 100818677 103024856 Loss SLC30A7 Acute lymphoblastic leukemia
13 13911 1 100818677 103024856 Loss VCAM1 Acute lymphoblastic leukemia
14 13991 1 102370195 102561809 Deletion Acute lymphoblastic leukemia
15 14292 1 106673274 107678605 Loss NTNG1 Acute lymphoblastic leukemia
16 14293 1 106673274 107678605 Loss PRMT6 Acute lymphoblastic leukemia
17 14369 1 107716342 144004701 Loss ADAM30 Acute lymphoblastic leukemia
18 14370 1 107716342 144004701 Loss ADORA3 Acute lymphoblastic leukemia
19 14371 1 107716342 144004701 Loss AFARP1 Acute lymphoblastic leukemia
20 14372 1 107716342 144004701 Loss AHCYL1 Acute lymphoblastic leukemia
21 14373 1 107716342 144004701 Loss AKNAD1 Acute lymphoblastic leukemia
22 14374 1 107716342 144004701 Loss ALX3 Acute lymphoblastic leukemia
23 14375 1 107716342 144004701 Loss AMIGO1 Acute lymphoblastic leukemia
24 14376 1 107716342 144004701 Loss AMPD1 Acute lymphoblastic leukemia
25 14377 1 107716342 144004701 Loss AMPD2 Acute lymphoblastic leukemia
26 14378 1 107716342 144004701 Loss AP4B1 Acute lymphoblastic leukemia
27 14379 1 107716342 144004701 Loss ATP1A1 Acute lymphoblastic leukemia
28 14380 1 107716342 144004701 Loss ATP5F1 Acute lymphoblastic leukemia
29 14381 1 107716342 144004701 Loss ATXN7L2 Acute lymphoblastic leukemia
30 14382 1 107716342 144004701 Loss BCAS2 Acute lymphoblastic leukemia
31 14383 1 107716342 144004701 Loss BCL2L15 Acute lymphoblastic leukemia
32 14384 1 107716342 144004701 Loss C1orf103 Acute lymphoblastic leukemia
33 14385 1 107716342 144004701 Loss C1orf152 Acute lymphoblastic leukemia
34 14386 1 107716342 144004701 Loss C1orf161 Acute lymphoblastic leukemia
35 14387 1 107716342 144004701 Loss C1orf162 Acute lymphoblastic leukemia
36 14388 1 107716342 144004701 Loss C1orf183 Acute lymphoblastic leukemia
37 15383 1 115048600 115061038 Copy number NRAS Acute lymphoblastic leukemia
38 15429 1 115400000 222100000 Gain Acute lymphoblastic leukemia
39 15832 1 119869201 120436800 Loss HMGCS2 Acute lymphoblastic leukemia
40 15833 1 119869201 120436800 Loss NBPF7 Acute lymphoblastic leukemia
41 15834 1 119869201 120436800 Loss NOTCH2 Acute lymphoblastic leukemia
42 15835 1 119869201 120436800 Loss PHGDH Acute lymphoblastic leukemia
43 15836 1 119869201 120436800 Loss REG4 Acute lymphoblastic leukemia
44 15837 1 119869201 120436800 Loss ZNF697 Acute lymphoblastic leukemia
45 15979 1 120700000 169100000 Loss CREG1 Acute lymphoblastic leukemia
46 16426 1 124300000 247249719 Deletion Acute lymphoblastic leukemia
47 16427 1 124300000 247249719 Duplication Acute lymphoblastic leukemia
48 16474 1 125000000 249250621 Copy number Acute lymphoblastic leukemia
49 16502 1 12600000 16100000 Deletion Acute lymphoblastic leukemia
50 16592 1 128000000 185104377 Copy number Acute lymphoblastic leukemia
Sources

Expression for Leukemia, Acute Lymphoblastic

About this section
Search GEO for disease gene expression data for Leukemia, Acute Lymphoblastic.
Sources

Pathways for Leukemia, Acute Lymphoblastic

About this section

Pathways related to Leukemia, Acute Lymphoblastic according to KEGG:

36
# Name Kegg Source Accession
1 Transcriptional misregulation in cancer hsa05202

Pathways related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
MicroRNAs in cancer 36
11.51 MIR335 MIR223 MIR203A MIR155 MIR152
2
Hematopoietic Stem Cell Gene Regulation by GABP alpha/beta Complex 1
10.3 FLT3 ETV6
Sources

GO Terms for Leukemia, Acute Lymphoblastic

About this section

Biological processes related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 dendritic cell differentiation GO:0097028 9.16 MIR155 FLT3
2 gene silencing by miRNA GO:0035195 9.1 MIR335 MIR223 MIR203A MIR196B MIR155 MIR152
3 negative regulation of necrotic cell death GO:0060547 8.96 MIR223 MIR155

Molecular functions related to Leukemia, Acute Lymphoblastic according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA binding involved in posttranscriptional gene silencing GO:1903231 8.92 MIR223 MIR203A MIR155 MIR152
Sources

Sources for Leukemia, Acute Lymphoblastic

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....